Immunovia AB
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Jeff Borcherding
- Full Time Employees
- 13
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Medicon Village Lund SN Sweden 223 63
- IPO Date
- Dec 1, 2015
- Website
- immunovia.com
- Similar Companies
- Business
- Immunovia AB (publ) (IMMNOV.ST) is a Sweden-based diagnostic company that develops and commercializes blood tests for early detection of pancreatic cancer and autoimmune diseases using its proprietary IMMray platform, which employs antibody biomarker microarray analysis, machine learning, and bioinformatics to identify disease-specific biomarker signatures; core products include the recently launched PancreaSure blood test for high-risk pancreatic cancer detection at Stages 1-2 with 87.9% sensitivity in late-stage cases and 97.7% specificity, the earlier IMMray PanCa-d laboratory-developed test offered through U.S. and Swedish Dx laboratories, and diagnostic tools like IMMray SLE-d for lupus differentiation. Founded in 2007 and headquartered in Lund, Sweden, with clinical labs and key operations in the U.S. including North Carolina and Massachusetts, the company targets high-risk patients through surveillance programs at leading centers such as University of Pennsylvania, Northwestern University, Inova Schar Cancer Institute, and Hackensack Meridian Health. Recent developments encompass the commercial launch of PancreaSure on September 2, 2025, with adoption by 10 top U.S. pancreatic cancer centers and key opinion leader advocacy; a SEK 100 million rights issue completed in October 2025 raising net proceeds of SEK 90.3 million to fund commercialization, clinical utility studies, and Medicare reimbursement efforts targeting full coverage by 2026 at a preliminary rate of $897; a licensing agreement with Proteomedix for manufacturing independence and cost reduction; CAP accreditation for its North Carolina lab; peer-reviewed CLARITI study publication in Gastroenterology; and a bridge loan of SEK 20 million ahead of the rights issue, alongside NIH-funded prospective trials and a three-phase strategy shifting to revenue growth in 2027.
Company News
Immunovia AB (publ) (IMMVF) Q2 2026 Earnings Call Transcript
Immunovia AB (publ) (IMMVF) Q1 2026 Earnings Call Transcript
Immunovia AB (publ) (IMMVF) Q4 2025 Earnings Call Transcript
Immunovia AB (publ) (IMMVF) Q3 2025 Earnings Call Transcript
Immunovia provides further positive data from the VERIFI study of its next-generation pancreatic cancer test
Immunovia to host a webcast to share more data from the successful VERIFI clinical validation study
Immunovia announces another successful clinical validation of its next-generation pancreatic cancer test
Immunovia AB (Publ) presents Nomination Committee
Immunovia CEO and board members announce intention to fully exercise their TO2 warrants
Immunovia presents data from model development study at meeting of the PRECEDE pancreatic cancer research consortium
Immunovia presents data from model development study at 2024 AACR Advances in Pancreatic Cancer medical conference
Immunovia announces updated financial calendar
Immunovia to Significantly Restructure to Focus Resources on its Next-Generation Blood Test for Pancreatic Cancer Detection
Immunovia to present at Gilmartin Group's Emerging Growth Company Showcase